Skip to content
Heart icon (animated) heart icon (static)
Share
Download Report

Janssen Pharmaceutical Companies of Johnson & Johnson Selected Novel Therapies - Recent Approvals/Potential Filings* (2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)

Selective Highlights as of July 19, 2022

Novel Therapies APPROVED

Oncology

RYBREVANT (amivantamab)

Non Small Cell Lung Cancer

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed refractory Multiple Myeloma

Novel Therapies in REGISTRATION

Oncology

teclistamab (BCMA/CD3)

Relapsed Refractory Multiple myeloma

niraparib

Metastatic castration-resistant prostate cancer (mCRPC)
EU

Novel Therapies PLANNED FILINGS

Cardiovascular and Metabolism

RPGR AAV Gene Therapy

X-linked retinitis pigmentosa

aprocitentan

Difficult to treat hypertension

Milvexian (Factor XIa)

Prevention and Treatment of Thrombosis
Infectious Diseases and Vaccines

RSV Adult Vaccine

RSV vaccine

JNJ-3989 siRNA

HBV/HDV Co-infection
Immunology

Oral IL-23i

Psoriasis
Neuroscience

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms

Aticaprant

Adjunctive treatment for major depressive disorder

nipocalimab

Generalized Myasthenia Gravis
Oncology

TAR-200 (RIS/gemcitabine)

Bladder Cancer

talquetamab (GPRC5D/CD3)

Multiple myeloma

niraparib

Metastatic castration-resistant prostate cancer (mCRPC)
US
Pulmonary Hypertension

Macitentan 75mg

Pulmonary Arterial Hypertension
Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information. BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue